AUTHOR=Čerina Dora , Matković Višnja , Katić Kristina , Lovasić Ingrid Belac , Šeparović Robert , Canjko Ivana , Jakšić Blanka , Fröbe Ana , Pleština Stjepko , Bajić Žarko , Vrdoljak Eduard 

TITLE=Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice

JOURNAL=Pathology and Oncology Research

VOLUME=Volume 27 - 2021

YEAR=2021

URL=https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2021.1609963

DOI=10.3389/pore.2021.1609963

ISSN=1532-2807

ABSTRACT=Comprehensive genomic profiling (CGP) is gradually becoming an inevitable part of the everyday oncology clinical practice. It`s interpretation and optimal implementation of the results is one of the hot topics of the modern-day oncology. According to the recent findings, uterine cancer harbors a high level of gene alterations, but is still insufficiently explored. The primary goal of this project was to assess a proportion of patients with targetable mutation. Also, the aim was to define and emphasize potential opportunities as well as the problems we have faced in the in the first year of testing on the national level. We performed a multicentric, retrospective, nested cross-sectional analysis on the total population of Croatian patients with advanced/metastatic uterine cancer on whose tumors CGP was performed during 2020.
CGP on 32 patients’ tumor tissue revealed clinically relevant genomic alterations (CRGA) in 27 (84%) patients with a median of 3 (IQR 1-4) CRGA per patient. The most common CRGAs were those of phosphatide-inositol-3 kinases (PIK3) in 22 (69%) patients, with 13/22 (59%) of those patients harboring PIK3CA mutation. The next most common CGRAs were ARID1A and PTEN mutations in 13 (41%) and 11 (34%) patients respectively. Microsatellite status was determined as stable in 21 (66%) patients and determined as highly instable in 10 (31%) patients. High tumor mutational burden (≥10Muts/Mb) was reported in 12 (38%) patients. After CGP some kind of targeted therapy was suggested in 28 (88%).
CGP determined clinically relevant genomic alterations in significant majority of patients with metastatic uterine cancer defining it as rich ground for further positioning and development of precision oncology.